HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reckitt Struggles To Tame Enlarged Health Portfolio As Durex and Scholl Stumble In Q2

Executive Summary

Durex, Scholl and a number of regional OTC brands fell short of expectations in Q2 as RB reported like-for-like Health sales down by 1%. Analysts are now questioning whether the UK-based firm has expanded too fast and spread itself too thin in the global consumer health market as it struggles to get the most out of its diverse portfolio. 

You may also be interested in...



Reckitt Charges Into UK PPI Heartburn Space With Guardium

With its new esomeprazole-based heartburn and indigestion remedy, Guardium, Reckitt Benckiser is taking head on Pfizer’s well-established Nexium Control brand in the UK. The firm hopes that by associating Guardium with its own well-known heartburn brand Gaviscon, and by investing in a multi-million-pound marketing campaign and pharmacy education, it can carve for itself a significant slice of the UK’s gastrointestinal market.  

Reckitt Names New CEO To Ignite Growth And Lead Digital Transformation

Reckitt Benckiser has poached PepsiCo's global chief commercial officer, Laxman Narasimhan, to replace Rakesh Kapoor as the UK-based firm's CEO. Setting his stall out early, Narasimhan has made clear that RB's "capabilities and culture" need to change to make the company fit for the new digital world.

RB's OTC Sales Slump 9% In Q1 As Cold Season Fails To Materialize

Reckitt Benckiser was hit badly by the weak cold and flu season in the US and Europe at the start of 2019, causing its OTC sales to drop by 9%. Despite supplement sales also struggling, the firm insists it will still hit its revenue targets for the full year, with growth expected in the second half. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel